Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme

Author： Zimmermann Mathias   Unger Thomas  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.5, 2004-05, pp. : 1201-1208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension

By Schmieder Roland E  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2303-2310

Informa Healthcare

Access to resources Recommend Favorite

Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication

By Neldam Steen   Edwards Colin  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 345-352

Informa Healthcare

Access to resources Recommend Favorite

Blinded End Point Adjudication in the ‘Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Coronary Angioplasty in Acute Myocardial Infarction’ (DANAMI-2 Trial)

By  

Heart Drug, Vol. 3, Iss. 3, 2003-11 ,pp. : 127-133

Karger

Access to resources Recommend Favorite

Remodeling as an End-Point in Heart Failure Therapy

By Cohn Jay  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 1, 2004-01 ,pp. : 7-8

Springer Publishing Company

Access to resources Recommend Favorite

Improving blood pressure control rates by optimizing combination antihypertensive therapy

By Epstein Benjamin J  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 2011-2026

Informa Healthcare

Access to resources Recommend Favorite